Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: Evidence supporting the DNA pol γ hypothesis

AIDS

Volumn 20, Issue 5, 2006, Pages 675-684

  Lewis, William ^a   Kohler, James J ^a   Hosseini, Seyed H ^a   Haase, Chad P ^a   Copeland, William C ^b   Bienstock, Rachelle J ^b   Ludaway, Tomika ^a   McNaught, Jamie ^a   Russ, Rodney ^a   Stuart, Tami ^a   Santoianni, Robert ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

AIDS; Cardiomyopathy; Deoxynucleotide carrier; DNA polymerase; Heart; Mitochondria; Nucleoside reverse transcriptase inhibitor; Transgenic

Indexed keywords

ANTIRETROVIRUS AGENT; DEOXYRIBONUCLEOTIDE; DNA DIRECTED DNA POLYMERASE GAMMA; LAMIVUDINE; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; POLYPEPTIDE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; HEART LEFT VENTRICLE; MITOCHONDRION; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; DNA; DNA, MITOCHONDRIAL; ECHOCARDIOGRAPHY; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOBLOTTING; LAMIVUDINE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA, HEART; MODELS, MOLECULAR; MYOCARDIUM; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAVUDINE; ZIDOVUDINE;

EID: 33745067485     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000216367.23325.58     Document Type: Article

References (55)

1. Dolce V, Fiermonte G, Runswick MJ, Palmieri F, Walker JE. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci USA 2001; 98:2284-2288.
2. Palmieri F. Mitochondrial carrier proteins. FEBS Lett 1994; 346:48-54.
3. Palmieri F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Archiv - Eur J Physiol 2004; 447:689-709.
4. Rosenberg MJ, Agarwala R, Bouffard G, Davis J, Fiermonte G, Hilliard MS, et al. Mutant deoxynucleotide carrier is associated with congenital microcephaly. Nat Genet 2002; 32:175-179.
5. Carrozzo R, Bornstein B, Lucioli S, Campos Y, de la Pena P, Petit N, et al. Mutation analysis in 16 patients with mtDNA depletion. Hum Mutat 2003; 21:453-454.
6. Lewis W, Haase CP, Miller YK, Ferguson B, Stuart T, Ludaway T, et al. Transgenic expression of the deoxynucleotide carrier causes mitochondrial damage that is enhanced by NRTIs for AIDS. Lab Invest 2005; 85:972-981.
7. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2:812-822.
8. Joly V, Descamps D, Yeni P. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. AIDS Rev 2002; 4:128-139.
9. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-422.
10. Lewis W, Meyer RR, Simpson JF, Colacino JM, Perrino FW. Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochemistry 1994; 33:14620-14624.
11. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 1994; 74:344-348.
12. Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001; 276:23616-23623.
13. Velsor LW, Kovacevic M, Goldstein M, Leitner HM, Lewis W, Day BJ. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol Appl Pharmacol 2004; 199:10-19.
14. Raidel SM, Haase C, Jansen NR, Russ RB, Sutliff RL, Velsor LW, et al. Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am J Physiol Heart Circ Physiol 2002; 282:H1672-H1678.
15. Lewis W, Haase CP, Raidel SM, Russ RB, Sutliff RL, Hoit BD, et al. Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Lab Invest 2001; 81:1527-1536.
16. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy [see comments]. N Engl J Med 1990; 322:1098-1105.
17. Cote HC, Yip B, Asselin JJ, Chan JW, Hogg RS, Harrigan PR, et al. Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis 2003; 187:1972-1976.
18. Davani EY, Brumme Z, Singhera GK, Cote HC, Harrigan PR, Dorscheid DR. Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury.[see comment]. Crit Care (London) 2003; 7:176-183.
19. Graziewicz MA, Longley MJ, Bienstock RJ, Zeviani M, Copeland WC. Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia. Nat Struct Mol Biol 2004; 11:770-776.
20. Bienstock RJ, Copeland WC. Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase. Mitochondrion 2004; 4:203-213.
21. Sarafianos SG, Clark AD Jr, Das K, Tuske S, Birktoft JJ, Ilankumaran P, et al. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J 2002; 21:6614-6624.
22. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847-40857.
23. Lim SE, Ponamarev MV, Longley MJ, Copeland WC. Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs. J Mol Biol 2003; 329:45-57.
24. Robbins J. Remodeling the cardiac sarcomere using transgenesis. Annu Rev Physiol 2000; 62:261-287.
25. Lewis W. Use of the transgenic mouse in models of AIDS cardiomyopathy. AIDS 2003; 17 (suppl 1):S36-S45.
26. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744.
27. Lewis W, Copeland WC, Day B. Mitochondrial DNA depletion, oxidative stress and mutation: mechanisms of nucleoside reverse transcriptase inhibitor toxicity. Lab Invest 2001; 81:777-790.
28. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi JP, et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 1996; 93:3592-3597.
29. Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, et al. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998; 28:179-191.
30. Walker UA, Venhoff N, Koch EC, Olschewski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003; 8:463-470.
31. Cossarizza A, Mussini C, Vigano A. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders? Bioessays 2001; 23:1070-1080.
32. Cossarizza A, Pinti M, Moretti L, Bricalli D, Bianchi R, Troiano L, et al. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus- positive children with highly active antiretroviral therapy-related lipodystrophy. J Infect Dis 2002; 185:299-305.
33. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse- transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [comment]. Lancet 1999; 354:1112-1115.
34. Hirano M, Marti R, Ferreiro-Barros C, Vila MR, Tadesse S, Nishigaki Y, et al. Defects of intergenomic communication: autosomal disorders that cause multiple deletions and depletion of mitochondrial DNA. Semin Cell Dev Biol 2001; 12:417-427.
35. Elpeleg O. Inherited mitochondrial DNA depletion. Pediatr Res 2003; 54:153-159.
36. Lewis W, Papoian T, Gonzalez B, Louie H, Kelly DP, Payne RM, et al. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest 1991; 65:228-236.
37. Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003; 42:14711-14719.
38. Feng JY, Murakami E, Zorca SM, Johnson AA, Johnson KA, Schinazi RF, et al. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′- thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother 2004; 48:1300-1306.
39. Feng JY, Johnson AA, Johnson KA, Anderson KS. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 2001; 276:23832-23837.
40. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [see comments]. Lancet 1999; 353:2093-2099.
41. Eriksson S, Xu B, Clayton DA. Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase. J Biol Chem 1995; 270:18929-18934.
42. Kaguni LS. DNA polymerase gamma, the mitochondrial replicase 1. Annu Rev Biochem 2004; 73:293-320.
43. Lewis W. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antiviral Res 2003; 58:189-197.
44. Lamperth L, Dalakas MC, Dagani F, Anderson J, Ferrari R. Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Invest 1991; 65:742-751.
45. Lewis W, Gonzalez B, Chomyn A, Papoian T. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest 1992; 89:1354-1360.
46. Swartz MN. Mitochondrial toxicity-new adverse drug effects [editorial comment]. N Engl J Med 1995; 333:1099-1105.
47. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine- induced myopathy. Lancet 1991; 337:508-510.
48. Song S, Pursell ZF, Copeland WC, Longley MJ, Kunkel TA, Mathews CK. DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci USA 2005; 102:4990-4995.
49. Kunkel TA, Soni A. Exonucleolytic proofreading enhances the fidelity of DNA synthesis by chick embryo DNA polymerase-gamma. J Biol Chem 1988; 263:4450-4459.
50. Kunkel TA, Mosbaugh DW. Exonucleolytic proofreading by a mammalian DNA polymerase. Biochemistry 1989; 28:988-995.
51. Kaguni LS, Wernette CM, Conway MC, Yang-Cashman P. Structural and catalytic features of the mitochondrial DNA polymerase from Drosophila melanogaster embryos. In: Eukaryotic DNA replication. Cold Spring Harbor, NY: Cold Spring Harbor Laboratories; 1988. pp. 425-432.
52. McKee EE, Bentley AT, Hatch M, Gingerich J, Susan-Resiga D. Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc Toxicol 2004; 4:155-167.
53. Lewis W, Grupp IL, Crupp C, Hoit B, Morris R, Samarel AM, et al. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000; 80:187-197.
54. Lewis W, Miller YK, Haase CP, Ludaway T, McNaught J, Russ R, et al. HIV viral protein R causes atrial cardiomyocyte mitosis, mesenchymal tumor, dysrhythmia, and heart failure. Lab Invest 2005; 85:182-192.
55. Hart GJ, Orr DC, Penn CR, Figueiredo HT, Gray NM, Boehme RE, et al. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother 1992; 36:1688-1694.